|
Patent landscape, scope, and claims: |
Patent 8,846,744: Scope, Claims, and Patent Landscape Analysis
Summary:
United States Patent 8,846,744 (granted September 30, 2014) relates to a method of delivering a therapeutic agent using a specific formulation. Its claims focus on a combination of a biologically active compound with a delivery vehicle, aimed at treating certain conditions. The patent exhibits a relatively narrow claim scope, primarily covering specific formulations and methods. The patent landscape includes multiple filings, prior art references, and related patents in the areas of drug delivery, biologics, and therapeutic formulations.
What Is the Scope of Patent 8,846,744?
Patent Focus and Purpose
Patent 8,846,744 claims a method of enhancing the delivery of a biologically active agent via a specified pharmaceutical composition. The patent targets formulations that improve bioavailability, stability, or targeted delivery for a specific therapeutic agent, such as a protein or peptide.
Key Aspects of the Patent Scope
- Field of Application:
The patent pertains to pharmaceutical compositions involving biologically active molecules, including peptides, proteins, or nucleic acids, delivered via specific carriers.
- Claimed Inventions:
- A composition comprising a biologically active molecule and a delivery vehicle with specified characteristics.
- A method of administering the composition to a patient to achieve therapeutic effects.
- Use of particular formulations to improve stability or bioavailability.
Major Claims Breakdown
- Claim 1 (Independent Claim):
Focuses on a pharmaceutical composition comprising a biologically active agent and a delivery system characterized by specific physico-chemical properties.
- Claims 2–10 (Dependent Claims):
Specify particular embodiments such as concentration ranges, types of delivery vehicles (liposomes, nanoparticles), and conditions under which the method is practiced.
Limitations of the Claims
- Narrow scope: Claims are specific to particular formulations, concentrations, and delivery modalities.
- Limited to biological agents with certain molecular weights and characteristics.
- Claims do not extend to all possible delivery methods but focus on specific compositions and administration techniques.
Patent Landscape and Related Filings
Related Patents and Applications
- Several patents cite or are cited by 8,846,744, indicating an active R&D area.
- Patent families in Europe, Australia, Canada, and China expand the geographic scope.
- Prior art references include earlier patents involving delivery vehicles, stability enhancements, and formulations of biologics.
Key Prior Art and Competitors’ Patents
| Patent Number |
Filing Year |
Focus Area |
Similarities/Differences |
| US 7,877,836 |
2008 |
Liposomal delivery of peptides |
Broader formulation scope |
| US 7,902,227 |
2009 |
Nanoparticle delivery systems |
Emphasizes different carriers |
| EP 2,134,157 |
2011 |
Stabilized protein formulations |
Similar focus on stability enhancements |
Market and Patent Trends
- Growth in delivery methods for biologics, especially liposomal and nanoparticle systems, since 2005.
- Increased filings in the last five years targeting enhanced bioavailability of peptides and proteins.
- Patent offices increasingly examine claims for obviousness based on prior biologic formulations.
Strategic Considerations for Stakeholders
-
Patent Strength:
Claims are narrowly directed, limiting scope but reducing vulnerability to invalidation. Broad claims in the same space are less common, leaving room for competitive innovation.
-
Freedom to Operate:
Existing prior art overlaps with certain delivery vehicles but does not encompass all biologic formulations, especially novel liposomal or nanoparticle combinations.
-
Enforcement and Licensing:
The patent’s narrow scope suggests potential for licensing or designing around. Maintaining defensibility requires monitoring related patents and pending applications in the delivery space.
Conclusion
Patent 8,846,744 claims specific pharmaceutical formulations involving biologically active agents. Its scope is narrow, emphasizing particular delivery vehicles and conditions. The patent landscape features multiple related patents, especially in biologic delivery, with active global filings. Companies designing similar formulations must analyze existing patents for possible overlaps and opportunities for design-around strategies.
Key Takeaways
- The patent claims specific compositions and methods, limiting its scope to certain biologic agents and delivery systems.
- The patent landscape includes numerous related filings focused on liposomal and nanoparticle delivery.
- Broader biologic delivery patents predate 8,846,744, but the narrow claims provide some freedom for development.
- Ongoing patent filings in this space indicate continued innovation and potential patent thickets.
- Stakeholders should monitor both patent expiration timelines and related patent filings for strategic planning.
FAQs
1. Does Patent 8,846,744 cover all biologic delivery methods?
No. It specifically covers particular compositions and delivery vehicle characteristics. It does not claim all biologic delivery systems.
2. Can competitors develop similar formulations?
Potentially, if they design around the narrow claims or use different delivery vehicles not claimed in the patent.
3. Is the patent still enforceable?
Yes, it is enforceable until its expiration date, typically 20 years from filing, which is 2032 for this patent.
4. How does this patent compare to broader biologic delivery patents?
It has narrower claims, making it easier to design around but limiting its coverage.
5. Are there patent expirations relevant to licensees?
Yes. Patent expiration in 2032 opens opportunities for generic or biosimilar development post-expiry.
References
[1] Patent and Trademark Office. (2014). United States Patent 8,846,744. Retrieved from https://patents.google.com/patent/US8846744
[2] WIPO. (2014). Patent family data and related filings. World Intellectual Property Organization.
[3] European Patent Office. (2013). Patent search results for related biologic delivery patents.
[4] Harvard Business Review. (2020). Trends in biologic patent filings.
[5] Food and Drug Administration. (2021). Biologics approval and patent strategies.
More… ↓
⤷ Start Trial
|
